GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theralink Technologies Inc (OTCPK:THER) » Definitions » Cash Ratio

Theralink Technologies (Theralink Technologies) Cash Ratio : 0.00 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Theralink Technologies Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Theralink Technologies's Cash Ratio for the quarter that ended in Dec. 2023 was 0.00.

Theralink Technologies has a Cash Ratio of 0.00. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Theralink Technologies's Cash Ratio or its related term are showing as below:

During the past 13 years, Theralink Technologies's highest Cash Ratio was 3.94. The lowest was 0.01. And the median was 0.04.

THER's Cash Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.94
* Ranked among companies with meaningful Cash Ratio only.

Theralink Technologies Cash Ratio Historical Data

The historical data trend for Theralink Technologies's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralink Technologies Cash Ratio Chart

Theralink Technologies Annual Data
Trend Feb14 Feb15 Dec16 Dec17 Dec18 Dec19 Sep20 Sep21 Sep22 Sep23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1.50 0.10 0.11 0.03

Theralink Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 - - 0.03 -

Competitive Comparison of Theralink Technologies's Cash Ratio

For the Biotechnology subindustry, Theralink Technologies's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theralink Technologies's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theralink Technologies's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Theralink Technologies's Cash Ratio falls into.



Theralink Technologies Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Theralink Technologies's Cash Ratio for the fiscal year that ended in Sep. 2023 is calculated as:

Cash Ratio (A: Sep. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.998/39.835
=0.03

Theralink Technologies's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.024/57.785
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theralink Technologies  (OTCPK:THER) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Theralink Technologies Cash Ratio Related Terms

Thank you for viewing the detailed overview of Theralink Technologies's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Theralink Technologies (Theralink Technologies) Business Description

Traded in Other Exchanges
N/A
Address
15000 West 6th Avenue, Suite 400, Golden, CO, USA, 80401
Theralink Technologies Inc is a proteomics-based, precision medicine and molecular profiling company that specializes in patented Reverse Phase Protein Array (RPPA) and protein biomarker assay services that target multiple areas of oncology. The company provides precision oncology data through its Theralink Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. The firm is currently generating revenue with its multiple biopharma contracts and by testing breast cancer patients with its patented Theralink assay.
Executives
Danica Holley director 7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814
Matthew Wilson Schwartz director 15000 W. 6TH AVENUE, SUITE 400, GOLDEN CO 80401
Chilcott, Iii Thomas E. officer: Chief Financial Officer 373 INVERNESS PARKWAY, ENGLEWOOD CO 80122
Jeffrey Busch director 7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814
Yvonne Fors director 1201 MONSTER RD SW STE 350, RENTON WA 98057
Michael I Ruxin director, officer: Chief Executive Officer HAEMONETICS CORPORATION INCORPORATED, 400 WOOD ROAD, BRAINTREE MA 02184
Avant Diagnostics, Inc 10 percent owner 1050 30TH STREET NW, SUITE 107, WASHINGTON DC 20007
Brian Gill Barnett officer: Chief Executive Officer 230 N SPRINGER, LOS ALTOS CA 94024
Robert Neal Holcomb director PO BOX 535, ROLLING FORK MS 39159
Volnie Carlos Fernando Alaman 10 percent owner, officer: Chief Operating Officer-Vitel MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000
Odabachian Manuel Cosme director, 10 percent owner, officer: Global Operations GM-Vitel MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000
Daniel S. Hoverman director C/O ONCBIOMUNE PHARMACEUTICALS INC.,, 11441 INDUSTRIPLEX BLVD, SUITE 190, BATON ROUGE LA 70809
Rice Charles L Jr director C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113
Andrew Albert Kucharchuk director, officer: CFO & President 549 MILGATE PLACE, BATON ROUGE LA 70810
Jonathan Frederick Head director, officer: Chief Executive Officer 6144 HAGERSTOWN DRIVE, BATON ROUGE LA 70817

Theralink Technologies (Theralink Technologies) Headlines

From GuruFocus

Theralink� Technologies Announces Corporate Name Change

By PRNewswire PRNewswire 09-24-2020

Theralink� Technologies Announces an Update on its Securities

By PRNewswire PRNewswire 10-22-2021